<DOC>
	<DOCNO>NCT02013102</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy decitabine treatment Myelodysplastic Syndrome .</brief_summary>
	<brief_title>A Phase Ⅳ Study Decitabine Myelodysplastic Syndrome</brief_title>
	<detailed_description>Total subject : 240 , doseⅠgroup 120 patient , doseⅡgroup 120 patient . Subjects stratify randomize . If necessary , participant accept best supportive therapy .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Age≥18 ; The diagnosis MDS patient comply WHO2008 standard ; IPSS score≥0.5 ; WHO classification patient RCUD , RARS transfusiondependent RCMD ; ECOG PS score : 02 ; Expected survival≥3 month ; Serum bilirubin≤1.5*ULN , serum ALT AST≤2.5*ULN , serum Cr≤1.5*ULN ; Subjects sign informed consent form line GCP requirement . Can marrow biopsy ; Previously diagnose AML ; Received azacitidine decitabine treatment time ; Being diagnose malignancy prior 12 month ; Pregnant lactate woman ; Failure control systemic fungal , bacterial viral infection ; Known suspect allergy decitabine ; Known human immunodeficiency virus ( HIV ) hepatitis B C class active viral infection ; Have history neurological psychiatric disorder , include epilepsy dementia ; CTCAE 3 4 degree peripheral neuropathy ; According investigator 's judgment , concomitant disease serious safety hazard affect patient complete study patient ; Using experimental drug participate clinical trial prior one month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>